PO

Medius and SourceDay Join Forces to Revolutionize Procure-to-Pay Operations

Retrieved on: 
星期二, 四月 30, 2024
Spend, Organization, PO, Risk, ERP, Partnership, AP, Procurement, Automation, Risk management

Benefits of the combined Medius and SourceDay solution include:

Key Points: 
  • Benefits of the combined Medius and SourceDay solution include:
    Highest industry PO matching through 100% ERP data accuracy and advanced 3-way match rates yields fully autonomous, touchless invoice processing for both PO and non-PO invoices.
  • "At Medius, we're dedicated to empowering our customers with the best-in-class solutions, and our collaboration with SourceDay does exactly that," said Jim Lucier, CEO of Medius.
  • "SourceDay's collaboration with Medius creates a significant advancement in direct material procure-to-pay," said Xavier Olivera, Senior Analyst, Spend Matters.
  • The SourceDay and Medius partnership is now active, with solutions available to all current and prospective customers.

Medius and SourceDay Join Forces to Revolutionize Procure-to-Pay Operations

Retrieved on: 
星期二, 四月 30, 2024
Spend, Organization, PO, Risk, ERP, Partnership, AP, Procurement, Automation, Risk management

Benefits of the combined Medius and SourceDay solution include:

Key Points: 
  • Benefits of the combined Medius and SourceDay solution include:
    Highest industry PO matching through 100% ERP data accuracy and advanced 3-way match rates yields fully autonomous, touchless invoice processing for both PO and non-PO invoices.
  • "At Medius, we're dedicated to empowering our customers with the best-in-class solutions, and our collaboration with SourceDay does exactly that," said Jim Lucier, CEO of Medius.
  • "SourceDay's collaboration with Medius creates a significant advancement in direct material procure-to-pay," said Xavier Olivera, Senior Analyst, Spend Matters.
  • The SourceDay and Medius partnership is now active, with solutions available to all current and prospective customers.

Psirenity Health and Pickleball Ontario Sign a Three-Year Partnership

Retrieved on: 
星期三, 四月 24, 2024
PO, Health, Partnership

Psirenity Health will be the Official "Wellness Partner" of Pickleball Ontario

Key Points: 
  • Oakville, Ontario--(Newsfile Corp. - April 24, 2024) - Psirenity Health and Pickleball Ontario (PO) have finalized a three (3) year partnership agreement whereby Psirenity Health will be the "Official Wellness Partner" of PO.
  • "Pickleball Ontario is excited to partner with Psirenity Health.
  • "Psirenity Health is thrilled to partner with PO and we look forward to helping its members Live Better, Longer," said Bryan Jones, CEO of Psirenity Health.
  • We look forward to leveraging the expertise of Psirenity Health to further elevate the well-being of our community."

Maria Black to Elevate Compliance and Automation with Centric PLM

Retrieved on: 
星期三, 四月 17, 2024
IMPACT, PO, Centric Software, DPP, Cosmetics, Product lifecycle, Portobello Road, Partnership, Creative, Black, Automation, PLM, Gold, Documentation, Legislation, Centric, Multimedia, Individual, Growth

CAMPBELL, Calif., April 17, 2024 /PRNewswire-PRWeb/ -- Centric Software, the Product Lifecycle Management (PLM) market leader, proudly announces its partnership with Maria Black, a contemporary fine and fashion jewelry brand based in Copenhagen. Centric Software provides the most innovative enterprise solutions to plan, design, develop, source, buy, make, price, allocate, sell and replenish products such as fashion, outdoor, luxury, multi-category retail, grocery, food & beverage, cosmetics & personal care and consumer electronics to achieve strategic and operational digital transformation goals.  

Key Points: 
  • "We have a lot of new developments, and therefore a lot of information to organize in one central location," says Maria Black, Founder and Creative Director at Maria Black.
  • "What really pushed us on the decision to implement a PLM system was compliance," says Black.
  • "We are delighted that Maria Black has selected Centric Software as a partner to navigate the increasingly complex compliance and traceability landscape," says Chris Groves, CEO of Centric Software.
  • "We look forward to seeing how Centric PLM will modernize Maria Black's processes and support their future growth."

Canter Resources Appoints New CFO, Corporate Secretary, Provides Corporate Updates and Announces Annual General Meeting Date

Retrieved on: 
星期四, 三月 14, 2024
Cloud, OTC Markets Group, McMillan LLP, Tax, Growth, CFO, AGM, Head, Marketing, Suite, TSX, Annual general meeting, Streetwise, CAD, CRC, High Tide, USD, PO, Corporation, CPA

In a corresponding move, Sarah Hundal will step down from her CFO and Corporate Secretary role and support the new appointees during the transition.

Key Points: 
  • In a corresponding move, Sarah Hundal will step down from her CFO and Corporate Secretary role and support the new appointees during the transition.
  • We continue to augment the corporate group as we enter this exciting phase of growth for the Company."
  • Annual General Meeting: The Company also announces that it has set its Annual General Meeting (the "AGM") for April 25, 2024 at 10:00 am (Vancouver Time).
  • High Tide is a Vancouver-based consulting company established in 2018 that provides corporate communications and investor relations services for publicly traded companies.

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
星期一, 三月 18, 2024
Research, Epilepsy, PO, Seizure, Partnership, Risk, Patient, Tramadol, Acquisition, American Epilepsy Society, GABAA, Enrollment, NRF1, SBMA, Schedule, Hydromorphone, Society, Therapy, DSM-IV codes, Safety, GAERS, Morphine, Pain, FDA, AES, Annual general meeting, Food, Pharmaceutical industry

MIAMI, March 18, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the year ended December 31, 2023.

Key Points: 
  • “We made considerable progress across our pipeline of differentiated neurologic therapies in 2023," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • Pending additional financing, we look forward to progressing BAER-101 and IV tramadol for patients facing great unmet need.
  • R&D Expenses: Research and development expenses for the full year 2023 were $6.1 million, compared to $2.7 million in 2022.
  • G&A Expenses: General and administrative expenses for the full year 2023 were $4.2 million, compared to $5.3 million in 2022.

Guerrilla RF Reports Record Revenue for Fourth Quarter and Full Year 2023

Retrieved on: 
星期一, 四月 1, 2024
Mobile, Wireless, Technology, Contracts, Semiconductor, 5G, Satellite, Military, Telecommunications, Hardware, Defense, Element, SATCOM, Growth, Investment, OTCQX, Multimedia, Automotive industry, PO, Video game

Guerrilla RF, Inc. (OTCQX: GUER), a leading provider of state-of-the-art radio frequency (RF) and microwave semiconductors, today announced record fourth quarter and full year 2023 revenue.

Key Points: 
  • Guerrilla RF, Inc. (OTCQX: GUER), a leading provider of state-of-the-art radio frequency (RF) and microwave semiconductors, today announced record fourth quarter and full year 2023 revenue.
  • Fourth quarter 2023 revenue increased 93.6% over the same period in 2022, coming in at $4.7 million compared to $2.4 million for the year ago quarter.
  • View the full release here: https://www.businesswire.com/news/home/20240401361693/en/
    Guerrilla RF, Inc. (OTCQX: GUER), today announced record fourth quarter and full year 2023 revenue.
  • Fourth quarter 2023 revenue increased 93.6% over the same period in 2022, coming in at $4.7 million compared to $2.4 million for the year ago quarter.

Settle Launches Purchase Order Automatic 3-Way Matching, Revolutionizing Procurement Processes

Retrieved on: 
星期三, 三月 27, 2024
Online, AP, Risk, Accounting, QuickBooks, CPG, Automatic, Purchase order, POS, PO

NEW YORK, March 27, 2024 /PRNewswire/ -- Settle, the leading cash-flow management platform, today announced the launch of Automatic 3-Way Matching for Purchase Orders, designed for the evolving needs of hyper-growth e-commerce and CPG brands. This 3-way matching solution bolsters Settle's commitment to simplifying cash flow management by saving critical time for accounting and operations teams, and focusing on innovating to solve inventory complexity.

Key Points: 
  • In the past year, Settle has found that 47% of POs had inconsistencies versus their corresponding bills totaling more than $12 million in discrepancies identified for customers.
  • Customers can centralize their AP documents and workflows from purchase to pay without scouring through folders and emails.
  • "Our Automatic 3-Way Matching marks a significant leap forward in removing typical bottlenecks with extreme accuracy, efficiency, and control in cash flow management.
  • Settle's free basic plan offers creation and storage of unlimited purchase orders for any CPG and e-commerce brand.

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

Retrieved on: 
星期一, 三月 11, 2024
Receptor (biochemistry), DSM-IV codes, FAAN, GAERS, Safety, Society, PO, Generalized tonic–clonic seizure, Therapy, Patient, Epilepsy, Human, Pharmaceutical industry

MIAMI, March 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of epilepsy at the American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting on Wednesday, March 13, 2024.

Key Points: 
  • The Company's presentation details are as follows:
    Title: BAER-101, a Selective Potentiator of α2- and α3-containing GABAA Receptors, Fully Suppresses Spontaneous Cortical Spike-Wave Discharges in Genetic Absence Epilepsy
    BAER-101 underwent preclinical in vivo evaluation in SynapCell's GAERS model of absence epilepsy.
  • In the model, BAER-101 demonstrated full suppression of seizure activity with a minimal effective dose of 0.3 mg/kg, PO.
  • The effect was fast in onset and stable throughout the duration of testing.
  • The combination of safety and tolerability in hundreds of patients and the preclinical efficacy data support BAER-101’s continued development in a Phase 2a trial.

FOMO WORLDWIDE PROVIDES INVESTOR UPDATE; CALLS OUT FINRA; WILL CANCEL REVERSE SPLIT IF FINRA RULE 6490 REVIEW NOT CONCLUDED BY 02/26

Retrieved on: 
星期二, 二月 20, 2024
Diamond, HVAC, FOMC, City, Sale, IPO, Health, University, PO, History, FINRA, Organization, Telecommunications, Advisory board, OTC, Documentation, BIG, COB, EAF, Constitution, SST, INC, Jobber, Carbon, Business, Comment, FOMO, LED, Acquisition, Catholic Church, Corporate title, Thought, Nature, Government, World Bank, Letter, CUSIP, Voice over IP, AT&T, Negotiation, Security (finance)

Our CUSIP has been changed to Wyoming and is on its sixth reminder for activation by CUSIP Global Services.

Key Points: 
  • Our CUSIP has been changed to Wyoming and is on its sixth reminder for activation by CUSIP Global Services.
  • Further, we have requested that FINRA complete its Rule 6490 reviews of our ticker change, name change, and redomicile immediately.
  • Management believes FINRA is unreasonably withholding completion of its Rule 6490 reviews of FOMO’s corporate actions.
  • The Company will host an investor meeting next Wednesday February 28th at 5:00pm to update investors on its acquisitive growth strategy.